首页> 外文OA文献 >SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation

【2h】

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation

机译：Sun-LB75选择性RET抑制剂Selpercatinib（LOXO-292）的抗肿瘤活性在髓质甲状腺癌中是独立于特定的RET突变

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Maria E Cabanillas; Lori J Wirth; Eric J Sherman; Alexander Drilon; Benjamin Solomon; Bruce G Robinson; Jochen H Lorch; Caroline McCoach; Jyoti Patel; Sophie Leboulleux; Francis Worden; Taofeek K Owonikoko; Marcia S Brose; Matthew H Taylor; Vivek Subbiah; S Michael Rothenberg; Xin Huang; Edward Zhu; Pearl P French; Manisha H Shah;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer [J] . G. Oxnard, V. Subbiah, K. Park, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：OA12.07 ROXO-292的临床活性，一种高度选择性的RET抑制剂，RET融合+非小细胞肺癌患者
2. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors [J] . La Pietra Valeria, Sartini Stefania, Botta Lorenzo, European Journal of Medicinal Chemistry: Chimie Therapeutique . 2018,第期

机译：挑战临床无响应髓质甲状腺癌：新型RET抑制剂的发现和药理活性
3. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer [J] . BentzienF., ZuzowM., HealdN., Thyroid: official journal of the American Thyroid Association . 2013,第12期

机译：甲状腺髓样癌模型中卡波替尼（XL184）（RET，MET和VEGFR2的抑制剂）的体外和体内活性
4. Selective tyrosine kinase inhibitor, STI571, inhibitsgrowth of p53 mutant anaplastic thyroid cancer cellsby inducing S-G2 transition arrest [C] . Alexei P. Podtcheko, Satoshi Tsuda, Akira Ohtsuru International Consortium for Medical Care of Hibakusha and Radiation Life Science . 2003

机译：选择性酪氨酸激酶抑制剂，STI571，P53突变体的抑制性诱导S-G2过渡逮捕的抑制性甲状腺癌细胞
5. Understanding the many facets of RET/PTC oncogene activity in thyroid carcinoma: Transformation, inflammation, and antigenicity [D] . Wixted, Josephine Fox 2012

机译：了解甲状腺癌中RET / PTC致癌基因活性的许多方面：转化，炎症和抗原性
6. SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation [O] . Maria E Cabanillas, Lori J Wirth, Eric J Sherman, 2020

机译：Sun-LB75选择性RET抑制剂Selpercatinib（LOXO-292）的抗肿瘤活性在髓质甲状腺癌中是独立于特定的RET突变
7. OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer [O] . G. Oxnard, V. Subbiah, K. Park, 2018

机译：OA12.07 ROXO-292的临床活性，一种高度选择性的RET抑制剂，RET融合+非小细胞肺癌患者

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation

著录项

引文网络

相似文献

相关主题

期刊订阅